Nephros

Nephros EBIT Growth

The Year-over-Year EBIT Growth of Nephros (NEPH) as of Oct 29, 2026 is 19,000.00 %. In the previous year, Year-over-Year EBIT Growth was 100.38 % — a change of 18,828.71% (higher).

EBIT Growth

19,000.00 %

YoY

18,828.71%

Last updated:

Year-over-Year EBIT Growth of Nephros is 2025 19,000.00 % . Year-over-Year EBIT Growth of Nephros was 2024 100.38 % . It decreases by 18,828.71% higher compared to the previous year.

The Nephros EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-41.38 USD
Jan 1, 2019
1.14 USD
Jan 1, 2020
-37.96 USD
Jan 1, 2021
26.54 USD
Jan 1, 2022
-33.30 USD
Jan 1, 2023
63.25 USD
Jan 1, 2024
100.38 USD
Jan 1, 2025
19,000.00 USD
The Nephros EBIT Growth history
YEAREBIT GrowthYoY
19,000.00 %+18,828.71%
100.38 %+58.69%
63.25 %-289.93%
-33.30 %-225.47%
26.54 %-169.93%
-37.96 %-3,429.85%
1.14 %-102.75%
-41.38 %-308.34%
19.86 %+22.20%
16.25 %-157.68%
-28.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nephros Stock analysis

What does Nephros do? Nephros, Inc. generates revenue through its Water Filtration and Renal Products segments. The Water Filtration segment sells high-performance water purification filters for hospitals, healthcare facilities, dialysis centers, commercial facilities, military, and outdoor recreation markets. The Renal Products segment offers a second-generation hemodiafiltration system for end-stage renal disease patients. Products include ultrafiltration systems used in medical and commercial applications, with subsidiaries Biocon 1, LLC, Aether Water Systems, LLC, and Specialty Renal Products, Inc. supporting sales and development. The company's water filtration products are sold to hospitals, dialysis centers, and commercial facilities, while the hemodiafiltration system targets healthcare providers treating ESRD patients. Subsidiaries handle specialized development and distribution, ensuring market coverage across medical and commercial sectors. Revenue streams are derived from both segments, with products serving healthcare infrastructure and renal treatment needs. Nephros, Inc. focuses on medical device solutions for renal disease and water purification, leveraging its subsidiaries to expand market reach. The Water Filtration segment serves healthcare and commercial clients, while the Renal Products segment addresses ESRD treatment through advanced hemodiafiltration technology, creating a diversified revenue model. Nephros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nephros stock

Year-over-Year EBIT Growth of Nephros is 19,000.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Nephros since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Nephros historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Nephros

All Key Metrics — Nephros